Results 201 to 210 of about 158,092 (291)

Beyond Preeclampsia: Focal and Segmental Glomerulosclerosis Presenting as Nephrotic‐Range Proteinuria During Pregnancy, A Clinical Case Report

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
Nephrotic‐range proteinuria during pregnancy is not always preeclampsia. This case illustrates a steroid‐responsive tip‐variant podocytopathy with normal angiogenic biomarkers (sFlt‐1/PlGF), supporting a non‐placental origin. Renal biopsy confirmed the diagnosis, while concurrent CMV infection may have acted as a potential immunologic trigger ...
Sierra Acuña Ximena Rosario   +1 more
wiley   +1 more source

Gestational Diabetes and Long‐Term Risk of Maternal Kidney Disease: Systematic Review and Meta‐Analysis of Population Base Cohort Studies

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
GDM with and without DM was significantly associated with an increased risk of maternal CKD. GDM with DM had a synergistic effect on maternal CKD risk. Women who experience GDM during their pregnancy, especially those who later develop diabetes, should be well informed about their long‐term risk of kidney disease.
Mansour Bahardoust   +7 more
wiley   +1 more source

Vedolizumab induced acute interstitial nephritis. [PDF]

open access: yesOxf Med Case Reports
Fernandes D   +3 more
europepmc   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed   +6 more
wiley   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy